共 434 条
[1]
Aghajanian C(2012)OCEANS: a randomized, double-blind, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2039-2045
[2]
Blank SV(2010)Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with Lancet 376 245-251
[3]
Goff BA(2012) or J Clin Oncol 30 1009-1680
[4]
Judson PL(2012) mutations and recurrent ovarian cancer: a proof-of-concept trial Leukemia 26 1675-967
[5]
Teneriello MG(2008)Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors Nat Rev Cancer 8 957-917
[6]
Husain A(2005)A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma Nature 434 913-156
[7]
Sovak MA(2013)GammaH2AX and cancer Breast Cancer Res 15 R88-921
[8]
Yi J(2009)Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Drug Resist Updat 12 153-134
[9]
Nycum LR(2005)Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Nature 434 917-2519
[10]
Audeh MW(2009)PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications N Engl J Med 361 123-861